Zhongda Hospital, Medical School, Southeast University
Welcome,         Profile    Billing    Logout  
 12 Trials 
22 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Ling
AK0529-2007, NCT06775405: A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants

Recruiting
3
180
RoW
AK0529, Placebo
Shanghai Ark Biopharmaceutical Co., Ltd.
Respiratory Synctial Virus Infections
08/25
09/25
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
SURPASS-CN-INS, NCT05691712: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Completed
3
257
RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
07/24
07/24
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Recruiting
2
185
RoW
HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor
Hutchison Medipharma Limited
Marginal Zone Lymphoma, Follicular Lymphoma
04/24
12/24
NCT06455410: GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

Recruiting
2
216
RoW
GP, Adebrelimab, concurrent chemoradiotherapy (CCRT)
Sun Yat-sen University
Nasopharyngeal Carcinoma
06/26
06/28
NCT06730373: First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Recruiting
2
110
RoW
Disitamab Vedotin, Sintilimab, S-1, Trastuzumab, Oxaliplatin, Capecitabine, 5-FU, Cisplatin
Qilu Hospital of Shandong University
HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma
12/26
12/27
TRS00501001, NCT05395533: A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

Recruiting
1
152
RoW
Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005
Zhejiang Teruisi Pharmaceutical Inc.
CD20-positive B-cell Non-Hodgkin Lymphoma
12/23
12/24
OPTIMAL, NCT03084991: OPTical Coherence Tomography IMAging in Patients With Acute myocardiaL Infarction

Recruiting
N/A
4500
RoW
Harbin Medical University, Abbott
Acute Myocardial Infarction
07/21
12/22
PEACP, NCT04122573: Prospective Multicenter Study for Early Evaluation of Acute Chest Pain

Recruiting
N/A
10000
RoW
Coronary angiography, CT angiography of aorta, CTA, CT angiography of pulmonary arteries., Electrocardiogram, ECG, Cardiac Troponin, Biomarkers of myocardial injury
West China Hospital
Chest Pain, Acute Aortic Dissection, Pulmonary Embolism, Acute Myocardial Infarction Type 1, Acute Coronary Syndrome
10/21
10/22
NCT05227677: Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes

Active, not recruiting
N/A
200
RoW
GA guided anti-diabetic therapy adjustment, current guidelines to adjust treatment
Asahi Kasei Pharma Corporation
Type 2 Diabetes Mellitus
08/24
12/24
NCT06276309: Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors

Recruiting
N/A
300
RoW
Fujian Maternity and Child Health Hospital
Neuroendocrine Neoplasm, China, Women, Cervical Cancer, Cervical Lesion
12/24
02/25
NCT05282095: Effect of HPV Integration on Prognosis of Young Women With CIN2 in China

Recruiting
N/A
300
RoW
Follow up
Fujian Maternity and Child Health Hospital
Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions
12/25
05/26
APCSAHAODBO, NCT04017286: Relationship About Pregnancy Health and Offspring Developmental &Behavioral Outcomes

Recruiting
N/A
3000
RoW
Chen Li
Children Behavior Problem, Pregnancy
07/25
12/28
NCT05597709: Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China

Recruiting
N/A
2900
RoW
Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination
Wuxi Hisky Medical Technology Co Ltd, Zhongda Hospital, Medical School, Southeast University, Suzhou Municipal Hospital, Suzhou Fifth People's Hospital, Xuzhou Mining Group General Hospital, Nantong First People's Hospital, Changzhou Second People's Hospital, Huaian Second People's Hospital, Huaian Hospital, Taizhou Jiangyan Traditional Chinese Medicine Hospital, Yangzhou Jiangdu People's Hospital, Huaian Xuyi County People's Hospital
Type 2 Diabetes Mellitus in Remission, Metabolic Associated Fatty Liver Disease
06/23
06/27
NCT05707819: Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Recruiting
N/A
43
RoW
Sintilimab (PD-1 Antibody), PD-1
Cancer Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma, Sintilimab
12/23
12/28
Shi, Ruihua
NCT04028323: Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)

Recruiting
4
60
RoW
Terlipressin, Octreotide
Nanfang Hospital of Southern Medical University, LanZhou University, Zhongda Hospital, Medical School, Southeast University, Guangdong Second Provincial General Hospital, Xingtai People's Hospital, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Tianjin Second People's Hospital, The Second Hospital of Anhui Medical University, The Sixth People's Hospital of Shenyang, The Second Affiliated Hospital of Baotou Medical College
Renal Function Disorder, Acute Variceal Bleeding
07/20
10/22
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
CHESS1901, NCT03990753: Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (/APPHA1901)

Recruiting
N/A
1000
RoW
esophagogastroduodenoscopy
Nanfang Hospital of Southern Medical University, Southern Medical University, China, LanZhou University, Zhongda Hospital, Medical School, Southeast University, Guangdong Second Provincial General Hospital, Xingtai People's Hospital, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Tianjin Second People's Hospital, Zhejiang University Lishui Hospital, The Second Hospital of Anhui Medical University, The Sixth People's Hospital of Shenyang, Xi'an Gaoxin Hospital, King Chulalongkorn Memorial Hospital affiliated to Chulalongkorn University, Ankara University
Compensated Cirrhosis
06/21
06/22
Ju, Shenghong
NCT04028323: Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)

Recruiting
4
60
RoW
Terlipressin, Octreotide
Nanfang Hospital of Southern Medical University, LanZhou University, Zhongda Hospital, Medical School, Southeast University, Guangdong Second Provincial General Hospital, Xingtai People's Hospital, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Tianjin Second People's Hospital, The Second Hospital of Anhui Medical University, The Sixth People's Hospital of Shenyang, The Second Affiliated Hospital of Baotou Medical College
Renal Function Disorder, Acute Variceal Bleeding
07/20
10/22
NCT05475015: 3D-MRE for Assessing Cirrhosis and Portal Hypertension

Recruiting
N/A
100
RoW
3D-MRE, HVPG
Shengjing Hospital, Zhongda Hospital
Cirrhosis, Liver, Portal Hypertension
12/24
12/25

Download Options